Vaccination with a Lawsonia intracellularis subunit water in oil emulsion vaccine mitigated some disease parameters but failed to affect shedding

• Published in: Vaccine Vol. 42; no. 24; p. 126254
• Main Authors: Fourie, Kezia R., Jeffery, Alison, Chand, Dylan, Choudhary, Pooja, Ng, Siew Hon, Liu, Haoming, Magloire, Donaldson, Khatooni, Zahed, Berberov, Emil, Wilson, Heather L.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 24-10-2024; Elsevier Limited
• Subjects: Adjuvants; Animals; Antigens; Challenge; Diarrhea; Disease control; E coli; Economic importance; Hogs; Ileitis; Immune response; Immune system; Immunogenicity; Industrial development; Lawsonia intracellularis; Lesions; Mineral oils; Parameter identification; Parameter robustness; Protection; Protein expression; Proteins; Robustness; Shedding; Small intestine; Subunit; Swine; Vaccination; Vaccines; Canada; United States > US; Saskatchewan Canada; Subunit; Swine; Protection; Lawsonia intracellularis; Vaccination; Challenge
• ISSN: 0264-410X; 1873-2518; 1873-2518
• DOI: 10.1016/j.vaccine.2024.126254

Lawsonia intracellularis is the causative agent of ileitis in swine that manifests as slower weight gain, mild or hemorrhagic diarrhea and/or death in severe cases. As an economically important swine pathogen, development of effective vaccines is important to the swine industry. In developing a subunit vaccine with three recombinant antigens - FliC, GroEL and YopN – we wanted to identify a formulation that would produce robust immune responses that reduce disease parameters associated with Lawsonia intracellularis infection. We formulated these three antigens with four adjuvants: Montanide ISA 660 VG, Montanide Gel 02 PR, Montanide IMS 1313 VG NST, and Montanide ISA 61 VG in an immunogenicity study. Groups vaccinated with formulations including Montanide ISA 660 VG or Montanide ISA 61 VG had significantly more robust immune responses than groups vaccinated with formulations including Montanide Gel 02 PR or Montanide IMS 1313 VG NST. In the challenge study, animals vaccinated with these antigens and Montanide ISA 61 VG had reduced lesion scores, reduced lesion lengths, and increased average daily gain, but no reduction in shedding relative to the control animals. This work shows that this vaccine formulation should be considered for future study in a field and performance trial.